Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
Terminated · Phase 3 · NCT05288855
Conditions: Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
At a glance
- Research payments reported, 2025
- $2,492
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 9
About the trial
- Sponsor
- Aurinia Pharmaceuticals Inc.
- Tested
- Voclosporin (drug), Placebo Oral Capsule (drug)
- Dates
- Started 2023-10-10; completion 2025-07-03
- Results posted
- Not yet
The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescent and pediatric subjects with active lupus nephritis (LN).
From ClinicalTrials.gov, last updated 2026-02-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Aurinia Pharma U.S., Inc. reported $2,492 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Icahn School of Medicine at Mount Sinai $2,363
- Children's Hospital of Philadelphia, PA $129
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.